ZTS VS VRTX Stock Comparison
Performance
ZTS100/100
100/100
ZTS returned 16.56% in the last 12 months. Based on SPY's performance of -13.45%, its performance is above average giving it a score of 100 of 100.
VRTX57/100
57/100
VRTX returned 13.96% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 56 of 100.
Analyst Price Targets
ZTS75/100
75/100
21 analysts offer 12-month price targets for ZTS. Together, they have an average target of 0, the most optimistic target put ZTS at 0 within 12-months and the most pessimistic has ZTS at 0.
VRTX80/100
80/100
27 analysts offer 12-month price targets for VRTX. Together, they have an average target of 0, the most optimistic target put VRTX at 0 within 12-months and the most pessimistic has VRTX at 0.
Technicals
ZTS82/100
82/100
ZTS receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.
VRTX21/100
21/100
VRTX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.
Earnings
ZTS53/100
53/100
ZTS has missed earnings 2 times in the last 20 quarters.
VRTX56/100
56/100
VRTX has missed earnings 2 times in the last 20 quarters.
Profit
ZTS78/100
78/100
Out of the last 20 quarters, ZTS has had 19 profitable quarters and has increased their profits year over year on 11 of them.
VRTX87/100
87/100
Out of the last 20 quarters, VRTX has had 20 profitable quarters and has increased their profits year over year on 13 of them.
Volatility
ZTS50/100
50/100
ZTS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
VRTX52/100
52/100
VRTX has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
Dividend
ZTS35/100
35/100
ZTS's most recent dividend was $0.12 per share, based on a share price of $174.62. It was a payout ratio of 17.39% compared to their total earnings.
VRTX
"Dividend" not found for VRTX
All score calculations are broken down here to help you make more informed investing decisions
ZOETIS INC. Summary
New York Stock Exchange / ZTS
Healthcare
Drug Manufacturers - Specialty & Generic
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Vertex Pharmaceuticals Inc Summary
Nasdaq / VRTX
Healthcare
Biotechnology
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ZTS to other companies in the same or a similar industry.